# Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

> **NCT02421172** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Hidradenitis Suppurativa (Acne Inversa)

## Interventions

- **BIOLOGICAL:** CJM112
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02421172
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-13
- **Primary completion:** 2016-11-23
- **Final completion:** 2016-11-23
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02421172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02421172, "Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02421172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*